



6-1250 Waverley Street
Winnipeg, MB, Canada R3T 6C6
www.miraculins.com

Phone 204.453.1408
Fax 204.453.1546
info@miraculins.com

Miraculins Announces Closing of Acquisition of Scout DS[®] Non-Invasive Diabetes Screening Technology

WINNIPEG, Manitoba – August 1, 2013 - Miraculins Inc. (TSX-V:MOM), (“Miraculins” or the “Company”), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, is pleased to announce that it has closed the acquisition from VeraLight, Inc. (“VeraLight”) of all relevant assets, including intellectual property, licenses and regulatory approvals, inventories, data and marketing materials, relating to the SCOUT DS[®] technology, a ground-breaking diabetes screening technology that non-invasively measures changes in the composition of a person’s skin indicative of pre-diabetes and type 2 diabetes.

As previously announced on July 2, 2013, the purchase price for the SCOUT DS[®] technology consists of a combination of cash and common shares of Miraculins.

In connection with the closing of the transaction, Lisa Suennen, Chair of VeraLight’s board of directors, was appointed to the board of directors of Miraculins.

About the SCOUT DS[®] System

The SCOUT DS[®] system, is the first non-invasive diabetes screening system designed to provide a highly sensitive and convenient method for screening for pre-diabetes and type 2 diabetes based on the presence of diabetes-related biomarkers found in skin. Unlike current screening methods, a SCOUT DS[®] test requires no blood draw, no fasting, and no waiting for a lab result. The product has been used and validated in thousands of patients around the world.

About Miraculins Inc.

Miraculins is a medical diagnostic company focused on acquiring, developing and commercializing non-invasive tests for unmet clinical needs. A significant number of promising diagnostic opportunities remain un-commercialized because of the sizable gap between the discovery stage, when research institutions are typically involved, and the commercialization stage, when the larger commercial enterprises become interested. Miraculins has direct experience in bridging this gap. The Company’s PreVu[®] technology is a revolutionary new coronary artery disease risk assessment technology that measures cholesterol levels in a patient’s skin non-invasively, painlessly and without the need for fasting. Miraculins is also advancing a suite of biomarkers to aid in the early detection of the devastating disease of pregnancy known as preeclampsia. The lead marker in the Company’s preeclampsia program is partnered with Alere Inc., one of the world’s largest diagnostic companies. For more information visit www.miraculins.com.

For more information, please contact:

Christopher J. Moreau
President & CEO
Miraculins Inc.
Ph: 204-477-7599
Fax: 204-453-1596
info@miraculins.com

www.miraculins.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

PreVu[®] is a registered trademark of Miraculins Inc. All Rights Reserved. 2013.